
Opinion|Videos|March 4, 2024
SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer
Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
3
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
4
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
5













